Categories
News Press Releases

What Causes Foodborne Illness? Updates from the IFSAC Report

Salmonella is one of the causes of Foodborne Illness

The Interagency Food Safety Analytics Collaboration (IFSAC), a joint initiative of the FDA, CDC, and USDA-FSIS, has recently released its 2022 Annual Report on Foodborne Illness Source Attribution Estimates. This comprehensive report sheds light on the primary sources of foodborne illnesses caused by Salmonella, Escherichia coli O157, and Listeria monocytogenes, offering critical insights for food safety stakeholders.

Foodborne Pathogens and Their Sources

The 2022 report highlights the leading food categories associated with these pathogens, providing actionable data to reduce foodborne illness outbreaks:

Salmonella

  • Top Sources: Chicken, turkey, and seeded vegetables. 
  • Impact: One of the most prevalent causes of foodborne illnesses and hospitalizations, causing diarrhea, fever, and abdominal cramps. Can be life-threatening in young children, the elderly, and those with weakened immune systems. 
  • Key Considerations: Salmonella is often present in the intestines of animals, making cross-contamination a significant concern during food processing.
  • By The Numbers/Annual Statistics: Salmonella causes an estimated 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths in the United States every year. 
  • Prevention Strategies: Consumers should cook poultry thoroughly to 165°F (74°C), wash hands and surfaces after handling raw poultry, and thoroughly wash seeded vegetables. The industry should implement strict hygiene practices during processing and use appropriate antimicrobial treatments.

E. coli O157

  • Top Sources: Leafy greens and beef.
  • Impact: Causes severe diarrhea (often bloody), abdominal cramps, and vomiting. Can lead to kidney failure in young children.
  • Key Considerations: Can survive in acidic environments and at low temperatures, making it challenging to eliminate.
  • Prevention Strategies: Consumers should thoroughly wash leafy greens, cook beef to an internal temperature of 160°F (71°C), and avoid cross-contamination between raw meat and other foods. The industry should implement stringent hygiene practices during cultivation and processing of produce and use effective sanitation methods in beef processing plants.
  • By The Numbers/Annual Statistics: E. coli O157 causes an estimated 63,153 illnesses, 2,138 hospitalizations, and 20 deaths in the United States each year.

Listeria monocytogenes

  • Top Sources: Dairy products (especially soft cheeses), deli meats, and fruits.
  • Impact: Causes fever, muscle aches, and sometimes gastrointestinal symptoms. Can lead to severe complications like meningitis and sepsis, especially in high-risk groups.
  • Key Considerations: Listeria is unique because it can grow at refrigerator temperatures, making it a concern in ready-to-eat foods with longer shelf lives.
  • Prevention Strategies: Consumers, especially high-risk individuals, should avoid soft cheeses, deli meats, and unpasteurized dairy products and thoroughly wash fruits before consumption. The industry should maintain strict temperature control during processing and storage and implement environmental monitoring programs to detect Listeria in processing facilities.
  • By The Numbers/Annual Statistics: Listeria causes an estimated 1,600 illnesses, 1,500 hospitalizations, and 260 deaths in the United States annually.

How This Report Helps Improve Food Safety

The IFSAC report is a cornerstone resource for food industry professionals, public health officials, and policymakers. Its data enables:

  • Enhanced Risk Management: Identifying high-risk foods to prioritize safety measures.
  • Strengthened Compliance: Aligning practices with updated FDA and USDA regulations.
  • Informed Decision-Making: Supporting data-driven strategies to mitigate contamination risks.

Empowering Food Safety Stakeholders

The report’s actionable insights regarding foodborne illness can be applied across the food supply chain:

  • Manufacturers: Implement rigorous testing and preventive controls for high-risk products.
  • Retailers: Educate staff and consumers on safe handling practices.
  • Regulators: Focus inspections and resources on the most susceptible food categories.

A Call to Action for Safer Food Practices

IFSAC’s 2022 Annual Report emphasizes the importance of collaboration and proactive measures in combating foodborne illness. By addressing the identified sources, the food industry can play a pivotal role in reducing outbreaks and protecting public health.

To explore the full report and its findings, visit the FDA website.

Categories
Blog News

MoCRA GMP Delayed Until October 2025: What You Need to Know

MoCRA GMP
The U.S. Food and Drug Administration (FDA) has postponed the implementation of the Modernization of Cosmetics Regulation Act (MoCRA) Good Manufacturing Practices (GMPs) until October 2025.

Originally scheduled for December 29, 2024, this delay offers businesses additional time to prepare for compliance. Here’s what this means for companies navigating MoCRA compliance and how to leverage the extension to stay ahead.

MoCRA, signed into law in December 2022, marked a historic shift in cosmetics regulation by the FDA. Among its key provisions is the requirement for companies to adhere to Good Manufacturing Practices (GMP), ensuring product safety and quality throughout the manufacturing process. The aim is to modernize the cosmetics industry, offering enhanced consumer protections while aligning with global standards.

Why the delay and how it impacts cosmetics companies?

The FDA’s decision to delay MoCRA GMP until October 2025 stems from the need for more detailed regulatory guidance and industry feedback. While the agency works on refining these rules, businesses must still adhere to other MoCRA mandates, such as registration, product listing, and fragrance allergen labeling, which take effect sooner. Key deadlines to watch include the following:

  • Fragrance allergen labeling: Targeted for January 2026.
  • Registration and listing requirements: Enforcement begins mid-2024.

The postponement provides a critical window for companies to:

  1. Assess current practices: Conduct internal audits to evaluate compliance gaps in manufacturing processes.
  2. Develop compliance strategies: Create or update Standard Operating Procedures (SOPs) aligned with anticipated MoCRA GMP requirements.
  3. Invest in training: Educate teams on MoCRA compliance to ensure readiness when enforcement begins.

Steps to Take Now

While the delay grants more time, proactive measures can set your company up for success:

1. Register and List Products Early

Stay ahead by completing your MoCRA registration and product listings before the mid-2024 deadline. These foundational steps are critical to maintaining compliance.

2. Strengthen Documentation

Ensure meticulous record-keeping of manufacturing practices, ingredient sourcing, and testing protocols. These records will be vital once GMP enforcement begins.

3. Monitor FDA Updates

Keep an eye on the FDA’s announcements for the finalized GMP guidelines and adjust your strategies accordingly. Complying with MoCRA GMP standards ahead of schedule not only ensures regulatory readiness but also enhances brand trust and reputation. Companies that prioritize safety and transparency will likely gain a competitive edge in an increasingly regulated market.

Don’t Delay. Prepare Today

The FDA’s extension of the MoCRA GMP deadline provides an invaluable opportunity to get your processes in order. Use this time to ensure your business not only meets regulatory standards but also positions itself as a leader in product safety and quality.

If you’re unsure where to start, Quality Smart Solutions is here to help. Our team of compliance experts specializes in guiding businesses through MoCRA compliance, from registration to certification. Contact us today to ensure your business is prepared to thrive in this new era of cosmetics regulation.

Categories
Blog

What Are FDA Medical Device Classes?

Understanding the FDA classification system for medical devices is key to getting your product to market safely and efficiently. Knowing how the FDA medical devices are categorized can help you avoid setbacks and ensure compliance, whether you’re dealing with a simple tool or a life-saving implant.

But how exactly does the FDA determine a device’s class, and what does it mean for you? Keep reading to uncover the answers and learn how you can navigate the process with confidence.

Why Does the FDA Classify Medical Devices?

The U.S. Food and Drug Administration (FDA) categorizes medical devices into three classes: Class I, II, and III. Each class reflects the device’s risk level and the regulatory controls required to ensure safety and effectiveness.

  • Class I: Low-risk devices with minimal regulatory requirements.
  • Class II: Moderate-risk devices needing unique controls.
  • Class III: High-risk devices requiring premarket approval.

These classifications determine the level of scrutiny your product will face during the FDA approval process. Misunderstanding these classifications can lead to setbacks like penalties, recalls, or approval delays. By the end of this guide, you’ll know exactly where your product fits in the FDA medical devices system.

Class I Medical Devices: Simple and Low Risk

Class I medical devices pose the least risk to patients and are typically simple tools used in daily medical practice. They are common, affordable, and essential in healthcare settings. Class I devices account for nearly half of all FDA medical devices, making them the most common category.

These low-risk tools still require proper compliance to ensure safety for end-users. Some examples of Class I devices include:

  • Bandages and gauze
  • Examination gloves
  • Surgical sponges
  • Hand-held surgical instruments like forceps
  • Basic thermometers (non-electronic)

While most Class I devices are exempt from Premarket Notification (510(k)), they must meet General Controls, such as proper labelling, record-keeping, and adherence to quality system regulations.

Class II Medical Devices: Moderate Risk and Special Controls

Class II medical devices present a moderate risk to patients and healthcare providers. They require more oversight than Class I devices to ensure consistent safety and performance.

This classification makes up about 43% of all FDA medical devices, playing a critical role in diagnostics, treatment, and patient care while maintaining manageable risk levels. Examples include:

  • Blood pressure monitors
  • Syringes (non-automated)
  • Infusion pumps
  • Catheters
  • Ultrasound imaging tools
  • Powered wheelchairs

To achieve compliance, most Class II devices require Premarket Notification (510(k)) to demonstrate equivalence to an already-approved product. Additional Special Controls may apply, such as performance testing, labelling requirements, and post-market monitoring.

Class III Medical Devices: High Risk and Highly Regulated

Class III medical devices are critical for sustaining life, preventing serious health issues, or addressing significant risks if they malfunction. Due to their life-critical nature, these devices undergo the most rigorous testing and regulatory scrutiny.

Although Class III devices represent a smaller percentage of FDA medical devices, their impact is substantial. Examples of Class III devices include:

  • Pacemakers
  • Implantable defibrillators
  • Heart valves
  • Cochlear implants
  • Artificial joints like hip or knee replacements
  • Stents for heart or vascular conditions

Approval for Class III devices requires Premarket Approval (PMA), which involves extensive clinical testing to prove safety and efficacy. After approval, ongoing post-market monitoring is necessary to identify any long-term risks or complications.

Wellness Products in the Medical Device Category

Some general wellness products fall under the medical device category but are not regulated by the FDA, offering a faster pathway to market. These products are intended for general health and wellness, such as improving fitness or promoting relaxation, rather than diagnosing or treating medical conditions. Examples include: 

  • Fitness trackers 
  • Non-invasive heart rate monitors 
  • Apps promoting healthy habits 
  • Sleep monitors 

For more details on general wellness products that are exempt from FDA regulation, refer to the FDA’s guidance on general wellness products

What Happens When You Cannot Properly Classify Your Device?

Misclassifying a medical device can lead to significant setbacks, including regulatory fines, product recalls, or delayed market entry. When uncertainty arises, companies can submit a 513(g) request to the FDA for guidance, which provides:

  • Clarity on classification: The FDA evaluates your product and determines the appropriate device classification.
  • Regulatory pathway guidance: Information on what is required for approval or clearance.

While submitting a 513(g) request involves additional time and cost, it can prevent costly errors in the long term by ensuring your product is on the right regulatory path from the start. For companies unsure of their device’s classification, this is a critical step toward achieving compliance. Learn more about 513(g) requests in the FDA guidance document.

How to Identify Your Medical Device’s Class

Knowing where your product fits will save time, reduce errors, and ensure you complete the right approval process. It starts with understanding the FDA’s system and comparing your product to similar devices that have already been approved.

  1. Define the intended uses and indications for use: What does your device do, and who will use it?
  2. Assess the risk level: Consider the potential harm if the device malfunctions.
  3. Check FDA databases: Look up similar devices in the FDA medical devices Product Classification Database.
  4. Prepare the right submission: Based on the class, complete a 510(k) notification or PMA application.

When in doubt, consulting regulatory experts can save you time and ensure your device meets all FDA medical devices requirements.

Simplify Your Compliance Journey

Navigating the FDA classification system for medical devices doesn’t have to be overwhelming. By understanding the differences between Class I, II, and III medical devices, you can take the right steps to bring your product to market faster and safer.

Need help identifying your device’s classification and managing submissions? Reach out to our team for expert support and guidance in complying with FDA medical devices standards.

Categories
Blog News

FDA Updates Guidance on Genome-Edited Foods

FDA Updates Guidance on Genome-Edited Foods

The U.S. Food and Drug Administration (FDA) has published an update to its guidance for voluntary premarket engagement regarding foods derived from genome-edited plants. This initiative highlights the agency’s commitment to ensuring food safety while fostering innovation in agricultural biotechnology. 

The FDA’s update includes the release of an inventory of voluntary premarket meetings held with developers of genome-edited plant-based foods. These meetings are intended to provide a platform for early engagement, allowing developers to address potential safety and regulatory concerns before marketing their products. 

This inventory serves as a public resource, offering transparency into the types of products entering the market and the FDA’s role in ensuring their compliance with food safety standards. 

A Distinction in Premarket Processes 

The FDA’s guidance outlines two distinct premarket processes: 

  1. Voluntary Premarket Engagement: Designed for genome-edited foods with lower risk characteristics, this process allows developers to discuss their products and clarify regulatory expectations. 
  2. Voluntary Premarket Consultation: Recommended for products that may pose greater safety or regulatory challenges, this pathway involves a more comprehensive review process. 

As you can see, both processes are voluntary but provide developers with valuable insights to streamline their product’s market entry. 

A Growing Inventory 

The FDA’s inventory of voluntary premarket meetings is expected to expand as more developers engage with the agency. By maintaining this resource, the FDA aims to encourage transparency and provide a clearer understanding of the safety evaluations associated with genome-edited foods. 

Implications for Developers 

This update underscores the importance of proactive collaboration between food developers and the FDA. By participating in voluntary premarket engagement, developers can: 

  • Gain early feedback on potential safety issues. 
  • Ensure compliance with regulatory requirements. 
  • Expedite the commercialization of genome-edited products. 

Foods derived from genome-edited plants must meet Generally Recognized As Safe (GRAS) standards. GRAS status is granted when the FDA determines that a food is as safe as conventional foods. It involves a rigorous review of safety data, including toxicology and allergen testing, to ensure consumer health is protected. Because these foods involve genetic modifications, proving their safety is essential before they reach consumers.

This process might seem overwhelming, but you don’t have to go it alone. Experts like Quality Smart Solutions and GRAS Experts specialize in helping developers navigate GRAS requirements. Their guidance can save you time, ensure compliance, and streamline your journey to market. 

The Broader Context 

Genome editing has become a cornerstone of agricultural innovation, offering opportunities to enhance crop yields, improve nutritional content, and reduce environmental impacts. As these technologies evolve, the FDA’s guidance serves as a critical framework for balancing innovation with safety. 

The agency reaffirmed that all foods derived from genome-edited plants must meet the same rigorous safety standards as other foods, emphasizing its commitment to public health. 

Accessing the Guidance 

Developers and stakeholders can review the full guidance and inventory on the FDA’s website. The agency encourages developers to consider these resources as part of their product development and regulatory planning. 

For more information, visit the FDA’s official update. 

Categories
Blog

VHP Representative vs. Importer of Record: Key Differences

A veterinarian giving a pet multivitamins, representing compliance with Canadian veterinary health product (VHP) regulations.If you’re planning to bring veterinary health products (VHPs) into Canada, you’ve probably come across the terms VHP Canadian representative and VHP Importer of Record. Sounds technical, right? But don’t worry, it’s not as complicated as it seems! These roles may sound similar, but they have distinct responsibilities that are essential to your success in the Canadian market.

Understanding the differences between these two roles can save you a lot of time, money, and stress. To help you navigate these requirements with confidence, we’ve broken it all down for you. Keep reading to discover what these roles are all about and why you need both for smooth operations.

What is a VHP Canadian Representative?

A VHP Canadian representative is your trusted partner when it comes to meeting Canadian regulations. If you’re a foreign manufacturer selling VHPs in Canada, this role isn’t optional, it’s required. Essentially, they’re your regulatory guide, helping you navigate the rules and acting as your main contact with Health Canada. Their key responsibilities include:

  • Liaising with Health Canada regarding product registration.
  • Assisting in maintaining compliance with Canadian VHP regulations.
  • Addressing any queries or concerns related to product safety.

With a knowledgeable Canadian representative on your side, you’ll save time and avoid potential issues. Plus, they make it easier for you to focus on other parts of your business.

What is a VHP Importer of Record?

In contrast, the VHP Importer of Record is responsible for ensuring that products entering Canada meet all importation requirements. This individual or entity facilitates customs clearance and ensures compliance with Canadian import regulations. Responsibilities include:

  • Handling customs documentation and declarations.
  • Ensuring that imported VHPs meet Canadian standards.
  • Managing duties, taxes, and other import-related fees.

In other words, they’re the ones who make sure your products get from point A to point B without any hiccups.

How Do These Roles Work Together?

Although the VHP Canadian representative and VHP Importer of Record have separate responsibilities, they complement each other perfectly. A VHP Canadian representative acts as the liaison between the foreign manufacturer and Health Canada, ensuring product compliance and addressing regulatory concerns.

On the other hand, a VHP Importer of Record is responsible for managing the logistics and legalities of bringing VHPs into Canada, including customs clearance and meeting importation standards.

By working together, these roles ensure that both regulatory and logistical aspects are covered, giving you peace of mind and allowing you to focus on growing your business.

In essence, for a smooth and compliant entry into the Canadian market, both roles are essential, and without them, your business risks operational setbacks.

Partner with Quality Smart Solutions

At Quality Smart Solutions, we specialize in supporting VHP manufacturers and importers navigate the complexities of the Canadian regulatory landscape. By partnering with us, you can focus on growing your business while we handle the regulatory details.

Ready to simplify your Canadian operations? Explore our VHP services for Canada or contact us today to get started!

Categories
Blog News

Health Canada Infant Formula Policy Transition

Infant formulaAre you prepared for changes to Health Canada’s regulations on infant formulas and dietary products? The Interim Policy on Importation and Sale ends on December 31, 2024. To ensure compliance and long-term availability, you need to align your products with the Food and Drugs Regulations (FDR). Let’s explore what this means and how you can adapt.

What Is the Interim Policy?

Health Canada introduced the interim policy in 2022 to stabilize supply during shortages. It allowed temporary importation of products that didn’t fully comply with regulations.

Now, Health Canada aims to replace this temporary measure. By launching a transition strategy, it ensures all products meet Canadian standards for the future.

The policy will expire on December 31, 2024, for products that don’t participate in the transition strategy. After this date, Health Canada will remove non-compliant products from Appendix A.

Products imported before the deadline can still be sold. However, this is only possible while supplies last and within their shelf-life.

How to Transition Your Products

If your product appears in Appendix A, follow these steps to stay compliant:

  1. Engage with Health Canada: Work closely with Health Canada to meet FDR requirements.
  2. Monitor updates: Regularly check Appendix A for changes as products are evaluated.
  3. Secure approvals: Once compliant, your product will move to Health Canada’s online list of approved items.

Don’t wait until it’s too late. Start the transition process now to ensure uninterrupted market access. Compliant products will benefit from long-term availability in Canada. For infant formulas, this means:

  • Removal from Appendix A of the interim policy.
  • Addition to Health Canada’s official list of reviewed products, available in stores and pharmacies.

Take Action and Avoid Disruption

Ensure your products meet Health Canada’s requirements before the December 31, 2024, deadline. Proactively transitioning your products will prevent disruptions and maintain their market availability. Check Health Canada’s website to stay updated on regulatory changes and find helpful resources.

Quality Smart Solutions specializes in guiding businesses through Health Canada’s compliance requirements. Our expert team can assist with product evaluations, approvals, and seamless transitions to ensure your products remain available in the Canadian market. Contact us today to start your compliance journey and secure your market access for 2025 and beyond.

Categories
Blog

How to Sell NHPs on Amazon Canada: A Complete Guide

Herbal remedies are classified as natural health productsSelling natural health products (NHPs) on Amazon Canada is a lucrative opportunity to expand your business and reach millions of potential customers. However, navigating the process requires understanding and adhering to Canadian regulations, as well as Amazon’s specific policies for NHPs.

From securing the necessary approvals to optimizing your product listings and driving sales, there are key steps to ensure your success. In this guide, we’ll walk you through everything you need to know to get your NHP listed and start selling successfully. Keep reading to unlock actionable tips and insights.

Understanding NHP Regulations in Canada

Before you can sell your NHP on Amazon Canada, it must meet Health Canada’s regulatory requirements. Every NHP sold in Canada requires a Natural Product Number (NPN) or a Homeopathic Medicine Number (DIN-HM) to confirm it’s safe, effective, and properly labeled. Obtaining an NPN might seem complex, but by following these steps, you can navigate the process with confidence:

  1. Submit an application: Use Health Canada’s Natural Health Products Online System (NHP Online) to apply for your NPN.
  2. Provide evidence: Include supporting data, such as ingredient safety, dosage, and proposed health claims.
  3. Approval process: Once approved, you’ll receive your NPN, allowing you to legally sell your product in Canada as long as your label accurately reflects the product licence. The label must be in both French and English for sale in Canada.

Setting Up Your Amazon Canada Seller Account

After obtaining your NPN, it’s time to create your Amazon Canada seller account. Choose between Individual or Professional plans, depending on your sales volume. To streamline your process, consider these key points:

  • Category approval: Apply for approval to sell in the NHP category. Amazon requires documentation, such as your NPN and product labels.
  • UPC/EAN codes: Ensure your product has valid barcodes for Amazon listings.
  • Shipping and fulfillment: Decide whether to handle logistics yourself or use Fulfillment by Amazon (FBA) for faster delivery and Prime eligibility. Please note that if you are storing products manufactured outside of Canada prior to reaching distribution channels, these sites may require approval through a valid iNHP import site licence. Imported NHPs must be reviewed and released for sale by an active site licence holder. This process will take into consideration the certification requirements of any third party responsible for the licensable activities of your products, such as manufacturing, labelling, packaging, and storage.
     
     

Optimize Your NHP Listings

Your Amazon product listing is the cornerstone of your online sales strategy. It’s not just about informing potential customers but also about convincing them to buy. Start by incorporating relevant keywords in your product title and description. These could include terms like “Natural Health Products” and specific benefits of your product.

It’s also essential to emphasize your product’s unique features, such as organic ingredients or eco-friendly packaging. Pair these descriptions with high-quality images that present your product from various angles. For added impact, ensure the images look professional and include alt text, such as: “Natural health product approved by Health Canada.”

Staying Compliant with Amazon and Health Canada

Maintaining compliance is crucial to avoid penalties or account suspension. Here’s what to watch for:

  • Label accuracy: Ensure all labels meet Health Canada’s standards, including proper ingredient lists and claims.
  • Inventory management: Monitor stock levels and expiration dates to prevent customer complaints, alongside adherence to traceability requirements in the event of a recall.
  • Customer feedback: Respond promptly to reviews and questions to build trust and improve your ratings.

Driving Sales With Marketing

After setting up your product listing, marketing becomes the key to driving traffic and boosting sales. Consider leveraging Amazon Ads to target customers searching for products like yours. Sponsored Product Ads can place your listing at the top of search results, giving you greater visibility.

Another effective strategy is to optimize your product descriptions regularly by integrating trending keywords. Beyond Amazon, social media campaigns can further amplify your reach. Platforms like Instagram and Facebook are excellent for showcasing your product and connecting with potential buyers.

How We Can Help

Selling NHPs on Amazon Canada doesn’t have to be overwhelming. With the right preparation and strategies, you can turn this opportunity into a profitable venture. At Quality Smart Solutions, we specialize in helping businesses like yours navigate Health Canada regulations, optimize Amazon listings, and implement effective marketing campaigns. Contact us today or explore our NHP compliance services to get started on your journey to success.

Categories
Blog News

Health Canada Fees 2025 Guide

Canadian flag symbolizing Health Canada Fees 2025 and regulatory compliance.Are you ready for the upcoming changes to Health Canada Fees in 2025? These fees, effective from April 2025, impact businesses dealing with drugs, medical devices, and cannabis. With updates spanning licensing, submissions, and compliance requirements, staying informed is key to avoiding disruptions.

Health Canada is introducing a phased fee structure that ensures businesses contribute to maintaining high standards for product safety and efficacy. From updated pre-market evaluation fees for drugs and medical devices to regulatory costs for cannabis producers, these changes could affect your budget and planning.

Want to know how these updates might impact your operations? Keep reading to explore the details and learn how to navigate these fees effectively with expert tips from Quality Smart Solutions.

Medical Devices

If you’re in the medical device sector, you will encounter fees tied to your initial Medical Device License (MDL) Application. These fees vary based on the classification of your medical device. The following are the fees for an MDL application as of April 1, 2025:

  • Class 2 Devices: $632
  • Class 3 Devices: $13,926
  • Class 3 Devices (Near Patient): $29,664
  • Class 4 Devices: $30,199

Applicable MDL amendments are also subject to additional application fees.

If you wish to apply for a Medical Device Establishment License (MDEL), you will need to pay both the initial application fee and the annual license renewal fee each year. The following are MDEL fees as of April 1, 2025.

  • Application for a new MDEL and annual review of license: $5426

Annual fees for right to sell licensed devices also apply. The fee as of April 1, 2025 is $452. These fees support ongoing regulatory oversight, ensuring that devices meet safety and compliance standards.

Drugs (Drug Identification Number Registration)

For drugs for human use requiring a Drug Identification Number (DIN), Health Canada has detailed fees based on the type of submission:

  • New Active Substance: $606,286
  • Clinical and Non-Clinical Data with Chemistry: $313,944
  • Comparative Studies Only$70,750
  • Administrative Submissions: $1,002
  • Labelling only: $6,328
  • Disinfectant – Full review: $13,186
  • Drug identification number application – Labelling standards: $1,912

These fees cover the rigorous evaluation process, ensuring products meet Health Canada’s stringent standards.

Additionally, companies engaged in various activities must hold a Drug Establishment License (DEL) which requires annual renewal. Fees are determined by the scope of activities and the types of products handled. The DEL fees for 2025 are:

  • Fabrication – Sterile dosage form: $49,558
  • Importation: $38,265
  • Fabrication – Non-sterile dosage form: $36,740
  • Distribution: $19,531
  • Wholesaling: $11,398
  • Packaging/labelling: $7,164
  • Testing: $5,913
  • Building outside Canada (each): $1,088

DEL fees ensure that establishments meet Good Manufacturing Practices (GMP) standards, supporting the safety and quality of pharmaceutical products in Canada.

For drugs already holding a Drug Identification Number (DIN), companies are required to pay an annual “Right to Sell” fee. The fee are as follows:

  • Human drugs – Disinfectant: $1,730
  • Human drugs – Non-prescription: $3,334
  • Human drugs – Prescription: $5,531

These fees enable ongoing compliance monitoring and market authorization renewal.

Cannabis

For businesses operating in Canada’s cannabis industry, Health Canada Fees cover several areas, including application screening, security clearance, and regulatory oversight. As of now, Health Canada has not published updated cannabis-related fees for the fiscal year 2025-2026. The most recent fee adjustments, effective April 1, 2024, are as follows:

  • Application Screening Fee: $3,933 for a standard-level license or sale for medical purposes and $1,969 for a micro-level license.
  • Security Clearance Fee: $1,987 per individual requiring clearance.
  • Annual Regulatory Fee:
    • Micro Cultivator: If the cannabis revenue is $1 million or less, the greater of 1% of the cannabis revenue, and $2,500 OR if the cannabis revenue is greater than $1 million, the maximum amount plus 2.3% of the amount by which the cannabis revenue exceeds $1 million.
    • Standard Cultivator: The greater of 2.3% of gross revenue or a minimum of $23,000.

Navigating these fees is critical for maintaining compliance and ensuring uninterrupted operations.

Why It Matters

Missing deadlines or miscalculating Health Canada fees can lead to costly delays or penalties. By planning ahead and leveraging expert guidance, you can focus on what matters most: growing your business.

Regulatory compliance doesn’t have to be daunting. At Quality Smart Solutions, we provide expert guidance to help you stay informed and save money. Explore more about our services to see how we can support your regulatory journey.

For a complete overview of all fees, visit Health Canada’s Funding and Fees page$1,002$36,740$3,334

Subscribe to global regulatory updates

We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.